Canada
· Delayed Price · Currency is CAD Algernon Pharmaceuticals Statistics
Total Valuation
CSE:AGN has a market cap or net worth of CAD 2.44 million. The enterprise value is 2.35 million.
| Market Cap | 2.44M |
| Enterprise Value | 2.35M |
Important Dates
The next estimated earnings date is Friday, July 25, 2025.
| Earnings Date | Jul 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:AGN has 28.76 million shares outstanding. The number of shares has increased by 30.54% in one year.
| Current Share Class | 28.76M |
| Shares Outstanding | 28.76M |
| Shares Change (YoY) | +30.54% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 14.09% |
| Owned by Institutions (%) | 15.83% |
| Float | 24.70M |
Valuation Ratios
The trailing PE ratio is 7.88.
| PE Ratio | 7.88 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.73 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 8.74 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.08
| Current Ratio | 0.08 |
| Quick Ratio | 0.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 29.05% and return on invested capital (ROIC) is -102.44%.
| Return on Equity (ROE) | 29.05% |
| Return on Assets (ROA) | -25.89% |
| Return on Invested Capital (ROIC) | -102.44% |
| Return on Capital Employed (ROCE) | -107.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.38% in the last 52 weeks. The beta is 1.90, so CSE:AGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.90 |
| 52-Week Price Change | -41.38% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.09 |
| Relative Strength Index (RSI) | 53.01 |
| Average Volume (20 Days) | 39,459 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.52M |
| Pretax Income | 269,144 |
| Net Income | 269,144 |
| EBITDA | -1.50M |
| EBIT | -1.52M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 92,181 in cash and n/a in debt, giving a net cash position of 92,181 or 0.00 per share.
| Cash & Cash Equivalents | 92,181 |
| Total Debt | n/a |
| Net Cash | 92,181 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 1.42M |
| Book Value Per Share | 0.05 |
| Working Capital | -1.81M |
Cash Flow
| Operating Cash Flow | -2.88M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:AGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.54% |
| Shareholder Yield | n/a |
| Earnings Yield | 11.01% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 3, 2023. It was a forward split with a ratio of 4.
| Last Split Date | Mar 3, 2023 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |